Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion criteria

* Histologically or cytologically confirmed recurrent or refractory non-Hodgkin's lymphoma (NHL) of any histologic subtype * Indolent * Follicular small cleaved cell * Follicular mixed cell * Small lymphocytic * Mucosa-associated lymphoid tissue (MALT) * Monocytoid B-cell * Waldenstrom's macroglobulinemia * Aggressive * Follicular large cell * Diffuse large cell * Immunoblastic * Mantle cell * Ki-1+ NHL * Peripheral T-cell * Angiocentric and angioimmunoblastic * Transformed lymphoma * Bidimensionally measurable disease * No more than 3 prior treatment regimens as follows: * Primary radiotherapy is 1 regimen * Combined therapy with radiotherapy and chemotherapy is 1 regimen * Alternating therapy is 1 regimen * No known brain metastases * Performance status - ECOG 0-2 * Performance status - Karnofsky 50-100% * WBC count at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin normal * SGOT/SGPT no greater than 2.5 times upper limit of normal * Creatinine normal * Creatinine clearance at least 60 mL/min * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * No neuropathy greater than grade 1 * No history of allergy to platinum compounds or antiemetics * No uncontrolled illness * No active infection * Not pregnant or nursing * Fertile patients must use effective contraception * No concurrent colony-stimulating factors during first course of therapy * At least 4 weeks since prior chemotherapy * At least 4 weeks since prior radiotherapy * No other concurrent investigational drugs * No concurrent antiretroviral therapy for HIV-positive patients